- DURECT (DRRX -15.5%) priced its earlier announced underwritten public offering of 17.7M shares for gross proceeds of ~$42.5M.
- Underwriters granted 30-day option to to purchase up to an additional 2.66M shares.
- Proceeds to be used for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs.
- Offer close expected on or about Feb.8.
DURECT prices ~$43M stock offering
Recommended For You
About DRRX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
DRRX | - | - |
DURECT Corporation |